Display Settings:

Format

Send to:

Choose Destination

    Nature. 1996 Jul 25;382(6589):319-24.

    A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A.

    Yang XJ, Ogryzko VV, Nishikawa J, Howard BH, Nakatani Y.

    Laboratory of Molecular Growth Regulation, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892-2753, USA.

    The adenoviral oncoprotein E1A induces progression through the cell cycle by binding to the products of the p300/CBP and retinoblastoma gene families. A new cellular p300/CBP-associated factor (P/CAF) having intrinsic histone acetylase activity has been identified that competes with E1A. Exogenous expression of P/CAF in HeLa cells inhibits cell-cycle progression and counteracts the mitogenic activity of E1A. E1A disturbs the normal cellular interaction between p300/CBP and its associated histone acetylase.

    PMID: 8684459 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Click here to read